Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20417071 | 0.86 | CYP2A6 (0.35) | CYP2A6DYRK1ACA2CA12HTR2C | |
| SCHEMBL24253404 | 0.84 | LMNA (0.41) | CYP2A6CA2HTR2C | |
| SCHEMBL24253388 | 0.84 | LMNA (0.41) | CYP2A6CA2HTR2C | |
| SCHEMBL13209268 | 0.81 | GAA (0.34) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL22215544 | 0.81 | POLB (0.41) | CYP2A6CTNNB1WNT3A | |
| SCHEMBL13824571 | 0.81 | CA2 (0.37) | CYP2A6DYRK1ACA2CA12PTPRC | |
| SCHEMBL22796676 | 0.81 | POLB (0.41) | CYP2A6CA2CA12CTNNB1WNT3A | |
| SCHEMBL164774 | 0.75 | CYP2A6 (0.50) | CYP2A6DYRK1ACA2CA12PTPRC | |
| SCHEMBL25891142 | 0.74 | CYP2A6 (0.33) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL1041559 | 0.73 | CYP2A6 (0.48) | CYP2A6DYRK1ACA2CA12PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022109363-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9737516-B2 | Bicyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160213654-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-07-28 | — | — | US | disclosed |
| US-9315501-B2 | Bicyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150148375-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148375-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | CYP2A6 4458/4885DYRK1A 3115/4885CA2 4746/4885 |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | CYP2A6 1110/4885DYRK1A 4382/4885CA2 1520/4885 |
| US-20230151019-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | CYP2A6 901/4885DYRK1A 4575/4885CA2 1275/4885 |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | CYP2A6 743/4885DYRK1A 3939/4885CA2 141/4885 |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | CYP2A6 498/4885DYRK1A 4521/4885CA2 575/4885 |
| US-20230159546-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | CYP2A6 791/4885DYRK1A 4642/4885CA2 979/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | CYP2A6 624/4885DYRK1A 4508/4885CA2 872/4885 |
| US-20230174542-A1 | HETEROCYCLIC ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | CYP2A6 905/4885DYRK1A 4746/4885CA2 1852/4885 |
| US-20160213654-A1 | BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | CYP2A6 4458/4885DYRK1A 3115/4885CA2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.